Akoya Biosciences and Team SAMBAI Announce Selection of the PhenoCycler®-Fusion as the Foundational Spatial Proteomics Technology for Large-Scale Study to Address Cancer Inequities

Core Insights - Akoya Biosciences' PhenoCycler-Fusion platform will be utilized for a groundbreaking Biobank and Data Repository aimed at Cancer Equity Research, funded by the Cancer Grand Challenges initiative [1][4] - The SAMBAI team will analyze cancer outcomes in 40,000 individuals of African descent, focusing on breast, pancreatic, and prostate cancers, which have higher rates of aggressive tumor grades in this population [3][5] - The project is set to receive up to $25 million in funding from Cancer Grand Challenges to support its extensive research efforts [4] Company Overview - Akoya Biosciences is recognized as The Spatial Biology Company®, specializing in spatial phenotyping to enhance understanding of biology and human health [9] - The company provides a range of single-cell imaging solutions, including PhenoCode™ Panels and various PhenoCycler and PhenoImager instruments, catering to diverse research needs [9]